These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8336170)

  • 1. Is 3-hydroxykynurenine an endogenous neurotoxin in Huntington's disease?
    Guilarte TR; Eastman CL
    J Neurol Sci; 1993 Jun; 116(2):227-8. PubMed ID: 8336170
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease.
    Pearson SJ; Reynolds GP
    Neurosci Lett; 1992 Sep; 144(1-2):199-201. PubMed ID: 1436703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early kynurenergic impairment in Huntington's disease and in a transgenic animal model.
    Guidetti P; Reddy PH; Tagle DA; Schwarcz R
    Neurosci Lett; 2000 Apr; 283(3):233-5. PubMed ID: 10754231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease?
    Guidetti P; Schwarcz R
    Adv Exp Med Biol; 2003; 527():137-45. PubMed ID: 15206726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tryptophan metabolites and brain disorders.
    Stone TW; Mackay GM; Forrest CM; Clark CJ; Darlington LG
    Clin Chem Lab Med; 2003 Jul; 41(7):852-9. PubMed ID: 12940508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Huntington's disease and neurotoxins.
    Martin JB; Beal MF
    Ann N Y Acad Sci; 1992 May; 648():169-75. PubMed ID: 1386201
    [No Abstract]   [Full Text] [Related]  

  • 7. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
    Tan L; Yu JT; Tan L
    J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.
    Sathyasaikumar KV; Stachowski EK; Amori L; Guidetti P; Muchowski PJ; Schwarcz R
    J Neurochem; 2010 Jun; 113(6):1416-25. PubMed ID: 20236387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice.
    Guidetti P; Bates GP; Graham RK; Hayden MR; Leavitt BR; MacDonald ME; Slow EJ; Wheeler VC; Woodman B; Schwarcz R
    Neurobiol Dis; 2006 Jul; 23(1):190-7. PubMed ID: 16697652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased brain 3-hydroxykynurenine in Huntington's disease.
    Reynolds GP; Pearson SJ
    Lancet; 1989 Oct; 2(8669):979-80. PubMed ID: 2571888
    [No Abstract]   [Full Text] [Related]  

  • 11. Increased concentrations of the neurotoxin 3-hydroxykynurenine in the frontal cortex of HIV-1-positive patients.
    Sardar AM; Bell JE; Reynolds GP
    J Neurochem; 1995 Feb; 64(2):932-5. PubMed ID: 7830088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Huntington's disease, energy, and excitotoxicity.
    Beal MF
    Neurobiol Aging; 1994; 15(2):275-6. PubMed ID: 7838311
    [No Abstract]   [Full Text] [Related]  

  • 13. An investigation of the activities of 3-hydroxykynureninase and kynurenine aminotransferase in the brain in Huntington's disease.
    Pearson SJ; Meldrum A; Reynolds GP
    J Neural Transm Gen Sect; 1995; 102(1):67-73. PubMed ID: 8785025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Huntington's disease--recent progress in neuroscience].
    Kanazawa I
    Tanpakushitsu Kakusan Koso; 1990 May; 35(7 Suppl):1332-40. PubMed ID: 2141429
    [No Abstract]   [Full Text] [Related]  

  • 15. The quinolinic acid hypothesis in Huntington's chorea.
    Bruyn RP; Stoof JC
    J Neurol Sci; 1990 Jan; 95(1):29-38. PubMed ID: 2159984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central kynurenine pathway shift with age in women.
    de Bie J; Guest J; Guillemin GJ; Grant R
    J Neurochem; 2016 Mar; 136(5):995-1003. PubMed ID: 26670548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tryptophan metabolism and oxidative stress in patients with Huntington's disease.
    Stoy N; Mackay GM; Forrest CM; Christofides J; Egerton M; Stone TW; Darlington LG
    J Neurochem; 2005 May; 93(3):611-23. PubMed ID: 15836620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.
    Sapko MT; Guidetti P; Yu P; Tagle DA; Pellicciari R; Schwarcz R
    Exp Neurol; 2006 Jan; 197(1):31-40. PubMed ID: 16099455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO).
    Winkler D; Beconi M; Toledo-Sherman LM; Prime M; Ebneth A; Dominguez C; Muñoz-Sanjuan I
    J Biomol Screen; 2013 Sep; 18(8):879-89. PubMed ID: 23690293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid.
    Beal MF; Matson WR; Swartz KJ; Gamache PH; Bird ED
    J Neurochem; 1990 Oct; 55(4):1327-39. PubMed ID: 2144582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.